|Last Price$82.80||Day Change (%)-0.12%|
|Open Price$83.19||Day Change ($)-0.10|
|Day Range82.70–83.44||52-Week Range67.67–84.37|
As of Tue 03/11/2014 04:31 PM EST | USD
Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
Proteus Digital Health™, NHS England and UK Trade & Investment to Bring Transformative Digital Health Technology to the UK
More than a dozen analyst-approved foreign large-cap funds own these names.
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Wunderman’s Chris McLaren Shares Social Media Expertise at Conference Board Event
We don't expect to change our fair value estimate for Novartis NVS after seeing the strong fourth-quarter results the firm reported Thursday. Sales were in line with our expectations, and strong growth in operating income helped Novartis improve its profitability. Growth primarily came from the ...
Research and Markets: Investigation Report on China's Valsartan Market 2014-2018
Transgene launches a rights issue of €45.5 million euros at a price of 10 euros per share
Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis